Results
Mean age was 60.76 ± 4.94 years. 68 men were included for 2 years, 59 for 3 years, 54 for 4 years, 44 for 5 years, and 28 for 6 years. Declining numbers reflect the nature of the registry (patients are included after receiving 1 year of TRT) but not drop-out rates.
Background
Hypogonadism is associated with cardiometabolic risk. Several studies suggest that hypogonadism increases the risk of all-cause and cardiovascular mortality. While some short-term studies have been performed in men with CVD, there are no data on long-term effects of testosterone replacement therapy (TRT) in men with CVD.
Methods
In a prospective, cumulative, observational registry study from a single urologist's office, 300 men with testosterone ≤12.1 nmol/L received TU injections for up to 6 years. In this subgroup analysis, 68 men with a previous diagnosis of coronary artery disease (CAD; n=40) and/or a history of myocardial infarction (MI; n=40) and/or Stroke (n=6) were analyzed.
